Goldman Sachs’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Goldman Sachs’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-36,773	Closed	-$93.4K	–	6194
2023 Q1	$93.4K	Buy	36,773 +11,284	+44%	+$22.3K	﹤0.01%	5468
2022 Q4	$47.7K	Sell	25,489 -52,328	-67%	-$130K	﹤0.01%	5602
2022 Q3	$200K	Sell	77,817 -14,131	-15%	-$35.2K	﹤0.01%	5483
2022 Q2	$177K	Sell	91,948 -167,994	-65%	-$367K	﹤0.01%	5686
2022 Q1	$772K	Buy	259,942 +5,629	+2%	+$21.2K	﹤0.01%	5032
2021 Q4	$1.14M	Sell	254,313 -18,126	-7%	-$86K	﹤0.01%	4731
2021 Q3	$1.32M	Buy	272,439 +17,814	+7%	+$98.2K	﹤0.01%	4538
2021 Q2	$1.74M	Buy	254,625 +10,266	+4%	+$83K	﹤0.01%	4330
2021 Q1	$1.73M	Sell	244,359 -3,220	-1%	-$23.2K	﹤0.01%	4131
2020 Q4	$1.55M	Buy	247,579 +91,158	+58%	+$536K	﹤0.01%	3914
2020 Q3	$846K	Sell	156,421 -69,733	-31%	-$345K	﹤0.01%	4186
2020 Q2	$1.18M	Buy	226,154 +9,844	+5%	+$43.7K	﹤0.01%	3844
2020 Q1	$681K	Sell	216,310 -125,012	-37%	-$461K	﹤0.01%	4019
2019 Q4	$1.38M	Buy	341,322 +208,755	+157%	+$724K	﹤0.01%	3914
2019 Q3	$572K	Buy	132,567 +92,844	+234%	+$371K	﹤0.01%	4381
2019 Q2	$158K	Sell	39,723 -27,256	-41%	-$130K	﹤0.01%	4850
2019 Q1	$359K	Sell	66,979 -15,192	-18%	-$98.1K	﹤0.01%	4560
2018 Q4	$421K	Buy	82,171 +42,930	+109%	+$326K	﹤0.01%	4456
2018 Q3	$381K	Sell	39,241 -124,937	-76%	-$1.26M	﹤0.01%	4570
2018 Q2	$1.68M	Buy	164,178 +113,505	+224%	+$1.28M	﹤0.01%	3742
2018 Q1	$659K	Buy	50,673 +3,345	+7%	+$49.8K	﹤0.01%	4312
2017 Q4	$847K	Sell	47,328 -78,043	-62%	-$1.63M	﹤0.01%	4439
2017 Q3	$3.15M	Sell	125,371 -6,352	-5%	-$148K	﹤0.01%	3576
2017 Q2	$3.17M	Buy	131,723 +88,222	+203%	+$1.95M	﹤0.01%	3444
2017 Q1	$837K	Sell	43,501 -11,094	-20%	-$175K	﹤0.01%	4549
2016 Q4	$841K	Sell	54,595 -632	-1%	-$8.21K	﹤0.01%	4602
2016 Q3	$719K	Sell	55,227 -16,107	-23%	-$214K	﹤0.01%	4711
2016 Q2	$992K	Buy	+71,334	New	+$1.05M	﹤0.01%	4185
2015 Q2	–	Sell	-11,679	Closed	-$365K	–	7489
2015 Q1	$365K	Buy	+11,679	New	+$335K	﹤0.01%	5453
2013 Q4	–	Sell	-2,169	Closed	-$83K	–	6829
2013 Q3	$83K	Sell	2,169 -29	-1%	-$1.04K	﹤0.01%	6207
2013 Q2	$80K	Buy	+2,198	New	+$94.2K	﹤0.01%	5939

Other funds holding PRTK

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Goldman Sachs's PRTK Position: Q2 2023 in Review

Goldman Sachs sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2023, closing a stake of 36,773 shares — an estimated $93.4K sold.

Goldman Sachs first reported a position in PRTK in Q2 2013 and held it in 31 quarters. The position peaked at $3.17M in Q2 2017. 66 funds tracked by Wall St. Rank hold PRTK as of Q2 2023.

Goldman Sachs reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Goldman Sachs sold 36,773 Paratek Pharmaceuticals, Inc. shares in Q2 2023, an estimated $93.4K.
Goldman Sachs first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 31 quarters.
Goldman Sachs's Paratek Pharmaceuticals, Inc. position peaked at $3.17M in Q2 2017.
66 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2023.

Based on Goldman Sachs's 13F filing for Q2 2023, filed 15 Aug 2023.